# Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal Cancer

> **NCT04177875** · PHASE2 · UNKNOWN · sponsor: **Tongji Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Esophagus Cancer

## Interventions

- **DRUG:** Teripalimab

## Key facts

- **NCT ID:** NCT04177875
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-01
- **Primary completion:** 2021-04-30
- **Final completion:** 2022-04-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2019-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04177875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04177875, "Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04177875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*